Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$21.98 USD
-0.12 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.97 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RCKT 21.98 -0.12(-0.54%)
Will RCKT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCKT
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
Other News for RCKT
First Week of June 21st Options Trading For Rocket Pharmaceuticals (RCKT)
Baron Health Care Fund Q1 2024 Shareholder Letter
RCKT Crosses Below Key Moving Average Level
Optimistic Buy Rating for Rocket Pharmaceuticals Based on Strong Gene Therapy Pipeline and Expert Leadership
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)